Expression of CD44s in incidental prostate cancer is more strongly associated with gleason scores on subsequent radical prostatectomies than conventional prognostic parameters

Pathobiology

Volumn 76, Issue 6, 2009, Pages 286-292

  Gunia, Sven ^a   May, Matthias ^b   Koch, Stefan ^a   Dietel, Manfred ^a   Erbersdobler, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b St Elisabeth Clinic Straubing   (Germany)

Author keywords

CD44s, standard isoform; Gleason scores; Immunohistochemistry; Incidental prostate cancer; Radical prostatectomy

Indexed keywords

HERMES ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CONTROLLED STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; TRANSURETHRAL RESECTION;

ADENOCARCINOMA; AGED; ANTIGENS, CD44; COHORT STUDIES; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; INCIDENTAL FINDINGS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 72449171077     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000245894     Document Type: Article

References (17)

1. Van Andel G, Vleeming R, Kurth KH, De Reijke TM: Incidental carcinoma of the prostate. Semin Surg Oncol 1995; 11: 36-45.
2. Sheldon CA, Williams RD, Fraley EE: Incidental carcinoma of the prostate: a review of the literature and critical reappraisal of classification. J Urol 1980; 124: 626-631.
3. Sobin LH, Wittekind CH: TNM Classification of Malignant Tumors, ed 6. New York, Wiley-Liss, 2002, pp 172-175.
4. Melchior S, Hadaschik B, Thuroff S, Thomas C, Gillitzer R, Thuroff J: Outcome of radical prostatectomy for incidental carcinoma of the prostate. BJU Int 2009; 103: 1478-1481.
5. Kallakury BV, Yang F, Figge J, Smith KE, Kausik SJ, Tacy NJ, Fisher HA, Kaufman R, Figge H, Ross JS: Decreased levels of CD44 protein and mRNA in prostate carcinoma: correlation with tumor graDe and ploidy. Cancer 1996; 78: 1461-1469.
6. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847.
7. Paul R, Knebel C, Van Radenborgh H, Kubler H, Alschibaja M, Gunther M, Hartung R: Incidental carcinoma of the prostate: can we and should we recommend radical prostatectomy? (in German). Urologe A 2005; 44: 1054-1058.
8. Gunia S, Koch S, May M, Dietel M, Erbersdobler A: Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatectomies. Virchows Arch 2009; 454: 573-579.
9. Caballero OL, De Souza SJ, Brentani RR, Simpson AJ: Alternative spliced transcripts as cancer markers. Dis Markers 2001; 17: 67-75.
10. Omara-Opyene AL, Qiu J, Shah GV, Iczkowski KA: Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18. Lab Invest 2004; 84: 894-907.
11. Noordzij MA, Van Steenbrugge GJ, Verkaik NS, Schroder FH, Van der Kwast TH: The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin Cancer Res 1997; 3: 805-815.
12. Aaltomaa S, Lipponen P, Viitanen J, Kankkunen JP, Ala-Opas M, Kosma VM: Prognostic value of CD44 standard, variant isoforms and 6 and - catenin expression in local prostate cancer treated by radical prostatectomy. Eur Urol 2000; 38: 555-562.
13. Aaltomaa S, Lipponen P, Ala-Opas M, Kosma VM: Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer. Eur Urol 2001; 39: 138-144. (Pubitemid 32171179)
14. Ouhit A, Abd Elmageed ZY, Abdraboh ME, Lioe TF, Raj MH: In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. Am J Pathol 2007; 171: 2033-2039.
15. Robinson D, Aus G, Bak J, Gorecki T, Herder A, Rosell J, Varenhorst E: Long-term followup of conservatively managed incidental carcinoma of the prostate: a multivariate analysis of prognostic factors. Scand J Urol Nephrol 2007; 41: 103-109.
16. Theodoropoulos VE, Tsigka A, Mihalopoulou A, Tsoukala V, Lazaris AC, Patsouris E, Ghikonti I: Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications. Urology 2005; 66: 897-902.
17. Fernandez PL, Hernandez L, Farre X, Campo E, Cardesa A: Alterations of cell cycleregulatory genes in prostate cancer. Pathobiology 2002; 70: 1-10.